This innovative project represents the world’s first research database on the use of cannabis for medical purposes and places the province at the forefront of research in the field of medical cannabis.
The registry was launched in response to a call by the Collège des médecins du Québec (CMQ) for guidelines on the use of medical cannabis in accordance with new government regulations.
As of April 1, 2014, cannabis can only be prescribed “within a research framework,” as it is not a medically recognized treatment.
“This registry has been developed to address the lack of research data on the safety and efficacy of cannabis,” said principal investigator Dr. Mark Ware, director of Clinical Research of the Alan Edwards Pain Management Unit at the MUHC and associate professor in Family Medicine and Anesthesia at McGill University.
“We need this database to help develop and answer future questions on the medical use of cannabis, such as who uses it, for what reasons, through which methods, and at what dose.”
The Quebec Cannabis Registry will be used to compile and store clinical data collected directly from patients who use medical marijuana. The data will be gathered from sites and clinics across Quebec, and each participant will provide data for four years after recruitment.
Any licensed doctor practising in the province wishing to authorise cannabis for their adult patients can enrol participants in the registry.
HEALTH CANADA ESTIMATES 40,000 LEGALLY CONSUME CANNABIS
Health Canada estimates that over 40,000 Canadians legally consume cannabis to relieve symptoms from such diseases as multiple sclerosis, HIV, cancer or epilepsy.
“We need to improve our understanding of the real-world use of medical cannabis and to make these data available to other researchers and collaborators,” noted Dr. Ware.
“This is the first registry of cannabis users that has been designed to stimulate research and to broaden our knowledge of this field. The registry will eventually help us better understand the possible risks and benefits related to the use of this product.”
The CCIC is looking forward to working with Dr. Ware “on this province-wide project that will serve as a model for many other countries in the world,” said Dr. John Clark, president of the CCIC board of directors, who is also an anesthesiologist and a pain specialist at Dalhousie University in Halifax, Nova Scotia.
The CCIC is a non-profit organization, composed of physicians and researchers, that aims to advance the understanding of the role of cannabinoids in health and disease through research and education.
“For the registry to succeed, Quebec physicians have to effectively become researchers, and patients have to consent to be research subjects,” added Ware. “The data collected will not have any identifiable patient information in order to protect their privacy.”
Anonymous questionnaire data will be entered into a secure electronic database that will be hosted and managed by the McConnell Centre for Innovative Medicine of the RI-MUHC at the Glen site.
Over the long term, this ten-year project will result in a research database that will be made available to the international scientific community.
“There is no doubt as to the RI-MUHC’s leadership in the area of pain management. This growing field of research is perfectly in line with our drive for innovation,” said Dr. Vassilios Papadopoulos, executive director and chief scientific officer for the RI-MUHC.
“This registry will certainly be a springboard for new discoveries and will position researchers in Canada as world leaders.”
• Quebec Cannabis Registry’s web site: www.registrecannabisquebec.com.
• McConnell Centre for Innovative Medicine: www.rimuhc.ca/web/research-institute-muhc/about-clinical-trials.
The Quebec Cannabis Registry has been funded by a grant from the CCIC. In order to put this project in place, the CCIC received funding from the Collège des médecins du Québec along with Bedrocan Canada Mettrum Ltd. and Tweed Marijuana Inc.